Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Globe Newswire•04/11/2026•16:05 ET
0
Key Highlights
- ➤Larimar management to join Guggenheim Healthcare Innovation Conference November 9-11
- ➤Fireside chat scheduled November 10 at 10:00 AM EST
- ➤Nomlabofusp is being developed for Friedreich's ataxia
- ➤Larimar plans additional rare-disease fusion proteins using its delivery platform
BALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place in Boston, MA from November 9-11, 2026.
Date: Tuesday, November 10, 2026 Time: 10:00 AM EST Webcast Link: https://event.summitcast.com/view/
Get started
Create a free account to read the full story.